EF
SCLN

Empirical Finance’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Empirical Finance’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-315
Closed -$4K – 676
2016
Q4 		$4K Buy
+315
New +$3.15K ﹤0.01% 606

Other funds holding SCLN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Empirical Finance's SCLN Position: Q1 2017 in Review

Empirical Finance sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q1 2017, closing a stake of 315 shares — an estimated $4K sold.

Empirical Finance first reported a position in SCLN in Q4 2016 and held it in 1 quarter. The position peaked at $4K in Q4 2016. 136 funds tracked by Wall St. Rank hold SCLN as of Q1 2017.

  • Empirical Finance reported no remaining Sciclone Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
  • Empirical Finance sold 315 Sciclone Pharmaceuticals Inc shares in Q1 2017, an estimated $4K.
  • Empirical Finance first reported a position in Sciclone Pharmaceuticals Inc in Q4 2016 and held it in 1 quarter.
  • Empirical Finance's Sciclone Pharmaceuticals Inc position peaked at $4K in Q4 2016.
  • 136 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q1 2017.

Based on Empirical Finance's 13F filing for Q1 2017, filed 11 May 2017.